Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

If you’re wondering what’s next for Teva Pharmaceutical Industries (NYSE:TEVA), the company’s latest move might catch your ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva ...

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

Saxenda is a brand name for the weight loss injectable medicine, Liraglutide. It was approved by the FDA for weight loss nearly a decade ago. Saxenda has been labeled ‘the skinny jab’ and the ‘miracle ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

A Blue Cross Blue Shield study of one decade worth of claims for Saxenda and Wegovy found 58% of patients quit the weight-loss drugs after 12 weeks.

In the ever-evolving symphony of weight loss medications, Saxenda (Liraglutide) has long taken center stage as a virtuoso in pharmaceutical solutions for shedding unwanted pounds. Yet, the search ...

A report by Blue Shield notes that more than half of people on weight loss medications such as Wegovy and Saxenda stop taking the drugs before they can reap the benefits ...